{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T12:44:41Z","timestamp":1792500281593,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Microbiol"],"DOI":"10.1186\/s12866-026-04853-8","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T23:43:06Z","timestamp":1772062986000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Assessing the efficacy of combined treatment using bedaquiline against clinical isolates of multidrug-resistant Mycobacterium tuberculosis in vitro and the macrophage model"],"prefix":"10.1186","volume":"26","author":[{"given":"Kamal","family":"Ahmadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahid","family":"Madadi-Goli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Azizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shima","family":"Hadifar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayereh","family":"Ebrahimzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morteza","family":"Masoumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahshid","family":"Nasehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Davar","family":"Siadat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abolfazl","family":"Fateh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzam","family":"Vaziri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"4853_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.612675","volume":"12","author":"A Allu\u00e9-Guardia","year":"2021","unstructured":"Allu\u00e9-Guardia A, Garc\u00eda JI, Torrelles JB. Evolution of drug-resistant Mycobacterium tuberculosis strains and their adaptation to the human lung environment. Front Microbiol. 2021;12:612675.","journal-title":"Front Microbiol"},{"key":"4853_CR2","doi-asserted-by":"publisher","unstructured":"Alashavi H, Daher M, Chorgoliani D, Saflo M, Zeidan M, Huseyinibrahim F, et al. Descriptive epidemiology of the tuberculosis service delivery project beneficiaries in Northwest Syria: 2019\u20132020. Front Public Health. 2021;9:672114. https:\/\/doi.org\/10.3389\/fpubh.2021.672114.","DOI":"10.3389\/fpubh.2021.672114"},{"issue":"2","key":"4853_CR3","doi-asserted-by":"publisher","first-page":"e0011722","DOI":"10.1128\/mbio.00117-22","volume":"13","author":"P Santucci","year":"2022","unstructured":"Santucci P, Aylan B, Botella L, Bernard EM, Bussi C, Pellegrino E, et al. Visualizing Pyrazinamide action by live Single-Cell imaging of phagosome acidification and Mycobacterium tuberculosis pH homeostasis. mBio. 2022;13(2):e0011722. https:\/\/doi.org\/10.1128\/mbio.00117-22.","journal-title":"mBio"},{"issue":"1","key":"4853_CR4","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1016\/S2666-5247(22)00359-7","volume":"4","author":"S Bagcchi","year":"2023","unstructured":"Bagcchi S. WHO\u2019s global tuberculosis report 2022. Lancet Microbe the. 2023;4(1):e20.","journal-title":"Lancet Microbe the"},{"key":"4853_CR5","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/j.ijid.2022.03.026","volume":"124","author":"S Tiberi","year":"2022","unstructured":"Tiberi S, Utjesanovic N, Galvin J, Centis R, D\u2019Ambrosio L, van den Boom M, et al. Drug resistant TB\u2013latest developments in epidemiology, diagnostics and management. Int J Infect Dis. 2022;124:S20\u20135.","journal-title":"Int J Infect Dis"},{"issue":"1","key":"4853_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12962-023-00479-z","volume":"21","author":"M Meskini","year":"2023","unstructured":"Meskini M, Madadi N, Ahmadi K, Vaziri F, Fateh A, Siadat SD. Tuberculosis prevention, diagnosis, and treatment financial profile during 2006\u20132021: PART A. Cost Eff Resour Alloc. 2023;21(1):68. https:\/\/doi.org\/10.1186\/s12962-023-00479-z.","journal-title":"Cost Eff Resour Alloc"},{"issue":"6","key":"4853_CR7","doi-asserted-by":"publisher","first-page":"e0270272","DOI":"10.1371\/journal.pone.0270272","volume":"17","author":"KA Molla","year":"2022","unstructured":"Molla KA, Reta MA, Ayene YY. Prevalence of multidrug-resistant tuberculosis in East Africa: a systematic review and meta-analysis. PLoS One. 2022;17(6):e0270272.","journal-title":"PLoS One"},{"issue":"1","key":"4853_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12941-024-00694-3","volume":"23","author":"N Madadi-Goli","year":"2024","unstructured":"Madadi-Goli N, Ahmadi K, Kamakoli MK, Azizi M, Khanipour S, Dizaji SP, et al. The importance of heteroresistance and efflux pumps in bedaquiline-resistant Mycobacterium tuberculosis isolates from Iran. Ann Clin Microbiol Antimicrob. 2024;23(1):36. https:\/\/doi.org\/10.1186\/s12941-024-00694-3.","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"4853_CR9","doi-asserted-by":"publisher","unstructured":"FalzonD, Sch\u00fcnemann HJ, Harausz E, Gonz\u00e1lez-Angulo L, Lienhardt C, Jaramillo E, et al. World health organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J. 2017;49(3):1602308. https:\/\/doi.org\/10.1183\/13993003.02308-2016.","DOI":"10.1183\/13993003.02308-2016"},{"key":"4853_CR10","doi-asserted-by":"publisher","unstructured":"PontaliE, Sotgiu G, Tiberi S, Tadolini M, Visca D, D\u2019Ambrosio L, et al. Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review. Eur Respir J. 2018;52(1):1800934. https:\/\/doi.org\/10.1183\/13993003.00934-2018.","DOI":"10.1183\/13993003.00934-2018"},{"issue":"28","key":"4853_CR11","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000007482","volume":"96","author":"TW Yang","year":"2017","unstructured":"Yang TW, Park HO, Jang HN, Yang JH, Kim SH, Moon SH, et al. Side effects associated with the treatment of multidrug-resistant tuberculosis at a tuberculosis referral hospital in South Korea: a retrospective study. Medicine. 2017;96(28):e7482. https:\/\/doi.org\/10.1097\/md.0000000000007482.","journal-title":"Medicine"},{"key":"4853_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12889-021-10698-9","volume":"21","author":"R Adisa","year":"2021","unstructured":"Adisa R, Ayandokun TT, Ige OM. Knowledge about tuberculosis, treatment adherence and outcome among ambulatory patients with drug-sensitive tuberculosis in two directly-observed treatment centres in Southwest Nigeria. BMC Public Health. 2021;21:1\u201314.","journal-title":"BMC Public Health"},{"issue":"1","key":"4853_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-48410-y","volume":"9","author":"K Yilancioglu","year":"2019","unstructured":"Yilancioglu K, Cokol M. Design of high-order antibiotic combinations against M. tuberculosis by ranking and exclusion. Sci Rep. 2019;9(1):11876.","journal-title":"Sci Rep"},{"issue":"2","key":"4853_CR14","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.drudis.2015.09.003","volume":"21","author":"KC Bulusu","year":"2016","unstructured":"Bulusu KC, Guha R, Mason DJ, Lewis RP, Muratov E, Motamedi YK, et al. Modelling of compound combination effects and applications to efficacy and toxicity: state-of-the-art, challenges and perspectives. Drug Discov Today. 2016;21(2):225\u201338.","journal-title":"Drug Discov Today"},{"key":"4853_CR15","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jgar.2021.02.017","volume":"25","author":"S Khoshnood","year":"2021","unstructured":"Khoshnood S, Goudarzi M, Taki E, Darbandi A, Kouhsari E, Heidary M, et al. Bedaquiline: current status and future perspectives. J Glob Antimicrob Resist. 2021;25:48\u201359.","journal-title":"J Glob Antimicrob Resist"},{"issue":"3","key":"4853_CR16","doi-asserted-by":"publisher","first-page":"02530","DOI":"10.1128\/aac","volume":"63","author":"H Ghajavand","year":"2019","unstructured":"Ghajavand H, Kargarpour Kamakoli M, Khanipour S, Pourazar Dizaji S, Masoumi M, Rahimi Jamnani F, et al. High prevalence of bedaquiline resistance in treatment-naive tuberculosis patients and verapamil effectiveness. Antimicrob Agents Chemother. 2019;63(3):02530\u201318. https:\/\/doi.org\/10.1128\/aac.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"4853_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2021.106509","volume":"59","author":"S Kim","year":"2022","unstructured":"Kim S, Louie A, Drusano GL, Almoslem M, Kim S, Myrick J, et al. Evaluating the effect of clofazimine against Mycobacterium tuberculosis given alone or in combination with pretomanid, bedaquiline or linezolid. Int J Antimicrob Agents. 2022;59(2):106509.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"4853_CR18","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1164\/rccm.200711-1736OC","volume":"179","author":"N Veziris","year":"2009","unstructured":"Veziris N, Ibrahim M, Lounis N, Chauffour A, Truffot-Pernot C, Andries K, et al. A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis. Am J Respir Crit Care Med. 2009;179(1):75\u20139.","journal-title":"Am J Respir Crit Care Med"},{"key":"4853_CR19","doi-asserted-by":"publisher","unstructured":"de Miranda Silva C, Hajihosseini A, Myrick J, Nole J, Louie A, Schmidt S, et al. Effect of linezolid plus bedaquiline against Mycobacterium tuberculosis in log phase, acid phase, and nonreplicating-persister phase in an in vitro assay. Antimicrob Agents Chemother. 2018;62(8). https:\/\/doi.org\/10.1128\/aac.00856-18.","DOI":"10.1128\/aac.00856-18"},{"issue":"7","key":"4853_CR20","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.1128\/AAC.01601-09","volume":"54","author":"VM Reddy","year":"2010","unstructured":"Reddy VM, Einck L, Andries K, Nacy CA. In vitro interactions between new antitubercular drug candidates SQ109 and TMC207. Antimicrob Agents Chemother. 2010;54(7):2840\u20136.","journal-title":"Antimicrob Agents Chemother"},{"key":"4853_CR21","doi-asserted-by":"publisher","first-page":"e55692","DOI":"10.7554\/eLife.55692","volume":"9","author":"A Giraud-Gatineau","year":"2020","unstructured":"Giraud-Gatineau A, Coya JM, Maure A, Biton A, Thomson M, Bernard EM, et al. The antibiotic bedaquiline activates host macrophage innate immune resistance to bacterial infection. eLife. 2020;9:e55692.","journal-title":"eLife"},{"issue":"3","key":"4853_CR22","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1128\/AAC.00898-06","volume":"51","author":"M Ibrahim","year":"2007","unstructured":"Ibrahim M, Andries K, Lounis N, Chauffour A, Truffot-Pernot C, Jarlier V, et al. Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis. Antimicrob Agents Chemother. 2007;51(3):1011\u20135.","journal-title":"Antimicrob Agents Chemother"},{"issue":"22","key":"4853_CR23","doi-asserted-by":"publisher","first-page":"10504","DOI":"10.1111\/jcmm.16980","volume":"25","author":"W Pu","year":"2021","unstructured":"Pu W, Zhao C, Wazir J, Su Z, Niu M, Song S, et al. Comparative transcriptomic analysis of THP-1\u2010derived macrophages infected with Mycobacterium tuberculosis H37Rv, H37Ra and BCG. J Cell Mol Med. 2021;25(22):10504\u201320.","journal-title":"J Cell Mol Med"},{"issue":"4","key":"4853_CR24","doi-asserted-by":"publisher","first-page":"4739","DOI":"10.1002\/jcp.27271","volume":"234","author":"S Hadifar","year":"2019","unstructured":"Hadifar S, Behrouzi A, Fateh A, Khatami S, Rahimi Jamnani F, Siadat SD, et al. Comparative study of interruption of signaling pathways in lung epithelial cell by two different Mycobacterium tuberculosis lineages. J Cell Physiol. 2019;234(4):4739\u201353.","journal-title":"J Cell Physiol"},{"key":"4853_CR25","doi-asserted-by":"publisher","unstructured":"Xu J, Wang B, Hu M, Huo F, Guo S, Jing W, et al. Primary Clofazimine and bedaquiline resistance among isolates from patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother. 2017;61(6). https:\/\/doi.org\/10.1128\/aac.00239-7.","DOI":"10.1128\/aac.00239-7"},{"issue":"1","key":"4853_CR26","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02919-20","volume":"60","author":"K Kaniga","year":"2022","unstructured":"Kaniga K, Hasan R, Jou R, Vasiliauskien\u0117 E, Chuchottaworn C, Ismail N, et al. Bedaquiline drug resistance emergence assessment in multidrug-resistant tuberculosis (MDR-TB): a 5-year prospective in vitro surveillance study of bedaquiline and other second-line drug susceptibility testing in MDR-TB isolates. J Clin Microbiol. 2022;60(1):e02919-20.","journal-title":"J Clin Microbiol"},{"key":"4853_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.754249","volume":"12","author":"S-H Wu","year":"2021","unstructured":"Wu S-H, Chan H-H, Hsiao H-C, Jou R. Primary bedaquiline resistance among cases of drug-resistant tuberculosis in Taiwan. Front Microbiol. 2021;12:754249.","journal-title":"Front Microbiol"},{"key":"4853_CR28","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ijid.2020.07.044","volume":"99","author":"J Yang","year":"2020","unstructured":"Yang J, Pang Y, Zhang T, Xian X, Li Y, Wang R, et al. Molecular characteristics and in vitro susceptibility to bedaquiline of Mycobacterium tuberculosis isolates circulating in Shaanxi, China. Int J Infect Dis. 2020;99:163\u201370.","journal-title":"Int J Infect Dis"},{"key":"4853_CR29","first-page":"11","volume":"2022","author":"B de Derendinger","year":"2022","unstructured":"Derendinger B, Dippenaar A, de Vos M, Huo S, Alberts R, Tadokera R et al. High frequency of bedaquiline resistance in programmatically treated drug-resistant TB patients with sustained culture-positivity in cape Town, South Africa. medRxiv. 2022:2022:11. 14.22282167.","journal-title":"medRxiv"},{"key":"4853_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12890-020-1172-4","volume":"20","author":"S Kabir","year":"2020","unstructured":"Kabir S, Tahir Z, Mukhtar N, Sohail M, Saqalein M, Rehman A. Fluoroquinolone resistance and mutational profile of GyrA in pulmonary MDR tuberculosis patients. BMC Pulm Med. 2020;20:1\u20136.","journal-title":"BMC Pulm Med"},{"issue":"1","key":"4853_CR31","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/molbev\/msz214","volume":"37","author":"RA Castro","year":"2020","unstructured":"Castro RA, Ross A, Kamwela L, Reinhard M, Loiseau C, Feldmann J, et al. The genetic background modulates the evolution of fluoroquinolone-resistance in Mycobacterium tuberculosis. Mol Biol Evol. 2020;37(1):195\u2013207.","journal-title":"Mol Biol Evol"},{"key":"4853_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-020-05112-5","volume":"20","author":"M Sayadi","year":"2020","unstructured":"Sayadi M, Zare H, Jamedar SA, Hashemy SI, Meshkat Z, Soleimanpour S, et al. Genotypic and phenotypic characterization of Mycobacterium tuberculosis resistance against fluoroquinolones in the northeast of Iran. BMC Infect Dis. 2020;20:1\u20137.","journal-title":"BMC Infect Dis"},{"key":"4853_CR33","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jgar.2020.11.017","volume":"24","author":"LN Welekidan","year":"2021","unstructured":"Welekidan LN, Skjerve E, Dejene TA, Gebremichael MW, Brynildsrud O, T\u00f8njum T, et al. Frequency and patterns of first-and second-line drug resistance-conferring mutations in Mycobacterium tuberculosis isolated from pulmonary tuberculosis patients in a cross-sectional study in Tigray Region, Ethiopia. J Glob Antimicrob Resist. 2021;24:6\u201313.","journal-title":"J Glob Antimicrob Resist"},{"key":"4853_CR34","doi-asserted-by":"publisher","unstructured":"Pang Y, Zong Z, Huo F, Jing W, Ma Y, Dong L, et al. In vitro drug susceptibility of bedaquiline, delamanid, linezolid, clofazimine, moxifloxacin, and Gatifloxacin against extensively drug-resistant tuberculosis in Beijing, China. Antimicrob Agents Chemother. 2017;61(10). https:\/\/doi.org\/10.1128\/aac.00900-17.","DOI":"10.1128\/aac.00900-17"},{"issue":"7","key":"4853_CR35","doi-asserted-by":"publisher","first-page":"e101311","DOI":"10.1371\/journal.pone.0101311","volume":"9","author":"GL Drusano","year":"2014","unstructured":"Drusano GL, Neely M, Van Guilder M, Schumitzky A, Brown D, Fikes S, et al. Analysis of combination drug therapy to develop regimens with shortened duration of treatment for tuberculosis. PLoS One. 2014;9(7):e101311.","journal-title":"PLoS One"},{"key":"4853_CR36","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.jgar.2019.06.013","volume":"19","author":"Y Chandramohan","year":"2019","unstructured":"Chandramohan Y, Padmanaban V, Bethunaickan R, Tripathy S, Swaminathan S, Ranganathan UD. In vitro interaction profiles of the new antitubercular drugs bedaquiline and delamanid with moxifloxacin against clinical Mycobacterium tuberculosis isolates. J Glob Antimicrob Resist. 2019;19:348\u201353.","journal-title":"J Glob Antimicrob Resist"},{"issue":"11","key":"4853_CR37","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.1128\/AAC.00766-06","volume":"50","author":"N Lounis","year":"2006","unstructured":"Lounis N, Veziris N, Chauffour A, Truffot-Pernot C, Andries K, Jarlier V. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration. Antimicrob Agents Chemother. 2006;50(11):3543\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"4853_CR38","doi-asserted-by":"publisher","first-page":"e0196756","DOI":"10.1371\/journal.pone.0196756","volume":"13","author":"RS Wallis","year":"2018","unstructured":"Wallis RS, Good CE, O\u2019Riordan MA, Blumer JL, Jacobs MR, Griffiss JM, et al. Mycobactericidal activity of bedaquiline plus Rifabutin or Rifampin in ex vivo whole blood cultures of healthy volunteers: A randomized controlled trial. PLoS ONE. 2018;13(5):e0196756. https:\/\/doi.org\/10.1371\/journal.pone.0196756.","journal-title":"PLoS ONE"},{"issue":"11","key":"4853_CR39","doi-asserted-by":"publisher","first-page":"5790","DOI":"10.1128\/AAC.01476-12","volume":"56","author":"B Lechartier","year":"2012","unstructured":"Lechartier B, Hartkoorn RC, Cole ST. In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2012;56(11):5790\u20133.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"4853_CR40","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.diagmicrobio.2019.02.012","volume":"94","author":"Y Pang","year":"2019","unstructured":"Pang Y, Jing W, Lu J, Zong Z, Huo F, Dong L, et al. No in vitro synergistic effect of bedaquiline combined with fluoroquinolones, linezolid, and clofazimine against extensively drug-resistant tuberculosis. Diagn Microbiol Infect Dis. 2019;94(4):361\u20134.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"1","key":"4853_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/srep34293","volume":"6","author":"S Ram\u00f3n-Garc\u00eda","year":"2016","unstructured":"Ram\u00f3n-Garc\u00eda S, del Gonz\u00e1lez R\u00edo R, Villarejo AS, Sweet GD, Cunningham F, Barros D, et al. Repurposing clinically approved cephalosporins for tuberculosis therapy. Sci Rep. 2016;6(1):34293.","journal-title":"Sci Rep"},{"issue":"4","key":"4853_CR42","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1093\/jac\/dky526","volume":"74","author":"MM Ruth","year":"2019","unstructured":"Ruth MM, Sangen JJ, Remmers K, Pennings LJ, Svensson E, Aarnoutse RE, et al. A bedaquiline\/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria. J Antimicrob Chemother. 2019;74(4):935\u201343.","journal-title":"J Antimicrob Chemother"},{"key":"4853_CR43","doi-asserted-by":"publisher","unstructured":"Le Moigne V, Raynaud C, Moreau F, Dupont C, Nigou J, Neyrolles O, et al. Efficacy of bedaquiline, alone or in combination with imipenem, against Mycobacterium abscessus in C3HeB\/FeJ mice. Antimicrob Agents Chemother. 2020;64(6). https:\/\/doi.org\/10.1128\/aac.00114-20.","DOI":"10.1128\/aac.00114-20"},{"issue":"4","key":"4853_CR44","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1183\/09031936.00162314","volume":"45","author":"ID Olaru","year":"2015","unstructured":"Olaru ID, von Groote-Bidlingmaier F, Heyckendorf J, Yew WW, Lange C, Chang KC. Novel drugs against tuberculosis: a clinician\u2019s perspective. Eur Respir J. 2015;45(4):1119\u201331.","journal-title":"Eur Respir J"},{"issue":"5","key":"4853_CR45","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.chom.2012.03.008","volume":"11","author":"J-J Kim","year":"2012","unstructured":"Kim J-J, Lee H-M, Shin D-M, Kim W, Yuk J-M, Jin HS, et al. Host cell autophagy activated by antibiotics is required for their effective antimycobacterial drug action. Cell Host Microbe. 2012;11(5):457\u201368.","journal-title":"Cell Host Microbe"},{"key":"4853_CR46","doi-asserted-by":"publisher","unstructured":"LyuX-L, Lin T-T, Gao J-T, Jia H-Y, Zhu C-Z, Li Z-H, et al. Effects of Bedaquiline on Antimicrobial Activity and Cytokine Secretion of Macrophages Infected with Multidrug-Resistant Mycobacterium tuberculosis Strains. Can J Infect Dis Med Microbiol. 2022;2022:2703635. https:\/\/doi.org\/10.1155\/2022\/2703635.","DOI":"10.1155\/2022\/2703635"},{"key":"4853_CR47","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.tube.2018.05.014","volume":"111","author":"C Genestet","year":"2018","unstructured":"Genestet C, Bernard-Barret F, Hodille E, Ginevra C, Ader F, Goutelle S, et al. Antituberculous drugs modulate bacterial phagolysosome avoidance and autophagy in Mycobacterium tuberculosis-infected macrophages. Tuberculosis. 2018;111:67\u201370. https:\/\/doi.org\/10.1016\/j.tube.2018.05.014.","journal-title":"Tuberculosis"},{"issue":"8","key":"4853_CR48","doi-asserted-by":"publisher","first-page":"e74082","DOI":"10.1371\/journal.pone.0074082","volume":"8","author":"C Manca","year":"2013","unstructured":"Manca C, Koo M-S, Peixoto B, Fallows D, Kaplan G, Subbian S. Host targeted activity of pyrazinamide in Mycobacterium tuberculosis infection. PLoS One. 2013;8(8):e74082.","journal-title":"PLoS One"}],"container-title":["BMC Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12866-026-04853-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-026-04853-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-026-04853-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T09:23:21Z","timestamp":1775035401000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12866-026-04853-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4853"],"URL":"https:\/\/doi.org\/10.1186\/s12866-026-04853-8","relation":{},"ISSN":["1471-2180"],"issn-type":[{"value":"1471-2180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"assertion":[{"value":"27 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki. The study was approved by the Ethics Committee of the Pasteur Institute of Iran (IR.PII.REC.1399.054), and written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"300"}}